Both dupilumab and mepolizumab were originally approved for asthma but were subsequently studied in patients with COPD who continue to experience symptoms and moderate-to-severe exacerbations despite ...
Respiratory Care Devices Market Report, published by Allied Market Research, suggests that the global respiratory care devices market was valued at $22.9 billion in 2023, and is projected to reach $47 ...